Literature DB >> 22045980

Socioeconomic burden of immune-mediated inflammatory diseases--focusing on work productivity and disability.

Philip Jacobs1, Robert Bissonnette, Lyn C Guenther.   

Abstract

Chronic disabling conditions, such as immune-mediated inflammatory diseases (IMID), adversely affect patients in terms of physical suffering and pain, impaired function, and diminished quality of life. These persistent relapsing diseases have a significant influence on individual employment status and work-related productivity. In addition to the significant burden on patients and their families, IMID represent a sizable burden to society due to high healthcare and non-healthcare related costs. Non-healthcare related, or indirect, costs - primarily associated with decreased work productivity, disability payments, and early retirements - are typically greater contributors than direct healthcare costs to the total costs associated with IMID. This article discusses the socioeconomic impact of several IMID, including rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis, and psoriasis.

Entities:  

Mesh:

Year:  2011        PMID: 22045980     DOI: 10.3899/jrheum.110901

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  25 in total

Review 1.  Applying nanomedicine in maladaptive inflammation and angiogenesis.

Authors:  Amr Alaarg; Carlos Pérez-Medina; Josbert M Metselaar; Matthias Nahrendorf; Zahi A Fayad; Gert Storm; Willem J M Mulder
Journal:  Adv Drug Deliv Rev       Date:  2017-05-12       Impact factor: 15.470

2.  Introduction to the special section: sustainability of work with chronic health conditions.

Authors:  William S Shaw; Torill H Tveito; Cécile R L Boot
Journal:  J Occup Rehabil       Date:  2013-06

Review 3.  Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?

Authors:  Andrew Keat; Alexander N Bennett; Karl Gaffney; Helena Marzo-Ortega; Raj Sengupta; Tamara Everiss
Journal:  Rheumatol Int       Date:  2016-12-29       Impact factor: 2.631

Review 4.  Nanomedicine delivers promising treatments for rheumatoid arthritis.

Authors:  Leena Kumari Prasad; Hannah O'Mary; Zhengrong Cui
Journal:  Nanomedicine (Lond)       Date:  2015-06-18       Impact factor: 5.307

5.  Tissue engineered skeletal muscle model of rheumatoid arthritis using human primary skeletal muscle cells.

Authors:  Catherine E Oliver; Hailee Patel; James Hong; Jonathan Carter; William E Kraus; Kim M Huffman; George A Truskey
Journal:  J Tissue Eng Regen Med       Date:  2021-11-20       Impact factor: 4.323

Review 6.  Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain.

Authors:  Vincent Y Ma; Leighton Chan; Kadir J Carruthers
Journal:  Arch Phys Med Rehabil       Date:  2014-01-21       Impact factor: 3.966

7.  Long-term etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using Canadian claims-level data.

Authors:  Majed Khraishi; Jelena Ivanovic; Yvonne Zhang; Brad Millson; Marie-Josee Brabant; Katia Charland; John Woolcott; Heather Jones
Journal:  Clin Rheumatol       Date:  2018-05-16       Impact factor: 2.980

8.  Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany.

Authors:  Niels Teich; Michael Bläker; Frank Holtkamp-Endemann; Eric Jörgensen; Andreas Stallmach; Susanne Hohenberger
Journal:  Inflamm Intest Dis       Date:  2020-12-18

9.  How much of the productivity losses among psoriasis patients are due to psoriasis.

Authors:  Anssi Mustonen; Kalle Mattila; Mauri Leino; Leena Koulu; Risto Tuominen
Journal:  BMC Health Serv Res       Date:  2015-03-04       Impact factor: 2.655

10.  Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study.

Authors:  Luca Degli Esposti; Diego Sangiorgi; Valentina Perrone; Sonia Radice; Emilio Clementi; Francesco Perone; Stefano Buda
Journal:  Clinicoecon Outcomes Res       Date:  2014-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.